5 November 2020 - PHARMAC would like to thank everyone who provided feedback on a proposal to fund two new medicines, empagliflozin (with and without metformin) and dulaglutide, for type 2 diabetes mellitus.

After having reviewed the consultation feedback, PHARNAC has determined that we require additional time to consider the matters raised before a decision can be made on the proposal. 

This means that a decision will not be made in time to implement the proposal from the earliest possible listing date of 1 December 2020 that was noted in the consultation.

Read PHARMAC press release